Wedbush Has Negative Estimate for Nuvation Bio Q3 Earnings

Nuvation Bio Inc. (NYSE:NUVB - Free Report) - Equities researchers at Wedbush reduced their Q3 2025 EPS estimates for Nuvation Bio in a research report issued on Monday, March 3rd. Wedbush analyst D. Nierengarten now expects that the company will post earnings of ($0.17) per share for the quarter, down from their prior forecast of ($0.16). Wedbush currently has a "Outperform" rating and a $5.00 price target on the stock. The consensus estimate for Nuvation Bio's current full-year earnings is ($0.36) per share. Wedbush also issued estimates for Nuvation Bio's Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.62) EPS, FY2026 earnings at ($0.73) EPS and FY2027 earnings at ($0.48) EPS.

Several other equities research analysts also recently commented on the stock. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $10.00 target price (up previously from $6.00) on shares of Nuvation Bio in a research note on Tuesday, January 7th. HC Wainwright decreased their price target on shares of Nuvation Bio from $11.00 to $10.00 and set a "buy" rating for the company in a report on Monday. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Nuvation Bio has an average rating of "Buy" and a consensus target price of $8.00.

Nuvation Bio Price Performance

Shares of Nuvation Bio stock traded down $0.15 during trading on Thursday, hitting $1.88. 3,381,863 shares of the company were exchanged, compared to its average volume of 2,530,605. The firm has a market capitalization of $631.06 million, a P/E ratio of -0.86 and a beta of 1.47. The firm's fifty day moving average price is $2.41 and its 200 day moving average price is $2.58. Nuvation Bio has a 1-year low of $1.67 and a 1-year high of $4.16.

Remove Ads

Institutional Investors Weigh In On Nuvation Bio

Institutional investors have recently added to or reduced their stakes in the stock. GSA Capital Partners LLP bought a new stake in shares of Nuvation Bio in the third quarter valued at about $172,000. Connor Clark & Lunn Investment Management Ltd. boosted its position in Nuvation Bio by 9.0% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 396,736 shares of the company's stock worth $909,000 after acquiring an additional 32,811 shares during the last quarter. Intech Investment Management LLC acquired a new stake in shares of Nuvation Bio in the third quarter valued at approximately $132,000. Charles Schwab Investment Management Inc. raised its holdings in shares of Nuvation Bio by 4.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,394,015 shares of the company's stock valued at $3,192,000 after purchasing an additional 60,590 shares during the last quarter. Finally, Meridian Wealth Management LLC lifted its position in shares of Nuvation Bio by 47.0% in the third quarter. Meridian Wealth Management LLC now owns 82,840 shares of the company's stock worth $190,000 after purchasing an additional 26,495 shares in the last quarter. 61.67% of the stock is owned by institutional investors.

About Nuvation Bio

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.